Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| XE XENEXenon Pharmaceuticals | $60.77+1.7% | $5.88B | 11 assetsPhase 3 | XEN1701 (Nav1.7 candidate)Phase 1 · Data readout | |
| XE XERSXeris Pharmaceuticals | $8.70+1.2% | $1.59B | 6 assetsStage unavailable | No dated catalyst | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $4.04+0.2% |
| $400.6M |
5 assetsPhase 3 |
Mavorixafor (CXCR4 inhibitor)Phase 3 · Data readout |
| XL XLOXilio Therapeutics | $9.23+0.0% | $60.7M | 4 assetsPhase 1/2 | Efarindodekin Alfa (XTX301)Phase 1/2 · Data readout |
| XN XNCRXencor Inc | $27.80+3.0% | $2.07B | 19 assetsPhase 2 | XmAb942Phase 2 · Data readout |
| XO XOMAXoma Corporation | $40.17+0.0% | $710.2M | 12 assetsPhase 3 | Ersodetug (Monoclonal Antibody)Phase 3 · Data readout |
| XX XXII22nd Century Group | $3.76-4.4% | $2.7M | 1 assetsStage unavailable | No dated catalyst |
| YM YMABY-mAbs Therapeutics | $8.61+0.0% | $391.2M | 7 assetsPhase 1 | GD2-SADAPhase 1 · Data readout |
| ZB ZBIOZenas BioPharma | $32.29+2.1% | $2.10B | 11 assetsPDUFA | Obexelimab (CD19xFcyRIIb)Phase 2 · Data readout |
| ZL ZLABZai Lab | $26.01-0.0% | $2.92B | 11 assetsPDUFA | Povetacicept (Pove) (APRIL/BAFF Inhibitor)PDUFA · Approval decision |
| ZL ZLDPFZealand Pharma | $50.51+1.0% | $3.44B | 13 assetsPhase 3 | Survodutide (GLP-1/Glucagon Agonist)Phase 3 · Data readout |
| ZN ZNTLZentalis Pharmaceuticals | $3.83-0.4% | $362.1M | 12 assetsPhase 2 | Azenosertib (ZN-c3) (oral inhibitor of WEE1) monoPhase 2 · Data readout |
| ZU ZURAZura Bio | $5.85+1.7% | $560.6M | 3 assetsPhase 2 | TibulizumabPhase 2 · Data readout |
| ZV ZVRAZevra Therapeutics | $11.87-0.2% | $704.9M | 8 assetsStage unavailable | No dated catalyst |
| ZV ZVSAZyVersa Therapeutics | $0.10-6.4% | $833,880 | 3 assetsPhase 2a | No dated catalyst |
| ZY ZYZYMERGEN INC | $2.43+0.0% | — | 1 assetsStage unavailable | No dated catalyst |
| ZY ZYMEZymeworks | $28.67+7.9% | $2.05B | 21 assetsPhase 3 | Zanidatamab (HER2) + chemotherapy + tislelizumabPhase 3 · Data readout |
| ZY ZYNEZynerba Pharmaceuticals | $1.30+0.0% | $901.4M | 2 assetsStage unavailable | No dated catalyst |